Opinion

Video

Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

Video content above is prompted by the following question:

  • In which patients might you consider first-line doublet therapy (venetoclax + BTK inhibitor)?
Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
John M. Burke, MD
Related Content
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine
December 10th 2024

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

Chronic Lymphocytic Leukemia | stock.adobe.com
December 10th 2024

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine
April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 10th 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

B-Cell Malignancies
December 9th 2024

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies